Quantum Biopharma (QNTM) Common Equity (2020 - 2026)
Quantum Biopharma (QNTM) posted Common Equity of -$1.4 million for Q1 2026, down 127.83% sequentially from $5.1 million in Q4 2025, and down 131.35% YoY from $4.5 million in Q1 2025.
Quantum Biopharma (QNTM) Common Equity (2020 - 2026) Analysis & Trends
Quantum Biopharma has reported Common Equity for 7 years, with the latest figure at -$1.4 million in Q1 2026.
- Quarterly Common Equity fell 131.35% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (down 131.35% YoY) and the FY2025 annual result came in at $5.1 million, down 51.13% from the prior year.
- Common Equity fell to -$1.4 million in Q1 2026 per QNTM's latest filing, from $5.1 million in the prior quarter.
- Over five years, Common Equity peaked at $30.5 million in Q4 2022 and troughed at -$1.4 million in Q1 2026.
- A 5-year average of $10.4 million and a median of $10.2 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2026: Common Equity rose 4.06% in 2024, then slumped 131.35% in 2026.
- Over 5 years, Common Equity stood at $30.5 million in 2022, then tumbled by 51.72% to $14.7 million in 2023, then slipped by 29.2% to $10.4 million in 2024, then tumbled by 51.13% to $5.1 million in 2025, then tumbled by 127.83% to -$1.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$1.4 million, $5.1 million, and $7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - | 7.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.95 Mn |
| Mar 31, 2026 | -1.42 Mn |
| Dec 31, 2025 | 5.10 Mn |
| Sep 30, 2025 | 7.51 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 4.53 Mn |
| Dec 31, 2024 | 10.44 Mn |
| Sep 30, 2024 | 15.35 Mn |
| Jun 30, 2024 | 10.20 Mn |
| Sep 30, 2023 | 14.75 Mn |
| Jun 30, 2023 | 15.55 Mn |
| Dec 31, 2022 | 30.54 Mn |
| Dec 31, 2021 | 54.13 Mn |
| Dec 31, 2020 | 36.31 Mn |